**Core Concept**
During pregnancy, the management of diabetes mellitus requires careful consideration of the safety of various oral hypoglycemic agents. The primary goal is to maintain glycemic control while minimizing the risk of fetal harm. This involves understanding the pharmacokinetics and pharmacodynamics of different oral hypoglycemics.

**Why the Correct Answer is Right**
Metformin is the preferred oral hypoglycemic agent in pregnancy due to its safety profile. It works by inhibiting hepatic glucose production and increasing insulin sensitivity. Metformin does not cross the placenta, thereby minimizing the risk of fetal hypoglycemia and other adverse effects. Studies have consistently shown that metformin is associated with a lower risk of congenital malformations and other pregnancy complications compared to other oral hypoglycemics.

**Why Each Wrong Option is Incorrect**
* **Option A**: Glyburide (glibenclamide) is a sulfonylurea that can cause fetal hypoglycemia due to its ability to cross the placenta. It is generally avoided in pregnancy unless absolutely necessary.
* **Option B**: Pioglitazone is a thiazolidinedione that has been associated with an increased risk of congenital malformations and other adverse effects in pregnancy. It is not recommended for use in pregnant women.
* **Option C**: Rosiglitazone is another thiazolidinedione that has been linked to an increased risk of congenital malformations and other pregnancy complications. It is not a safe option for pregnant women.

**Clinical Pearl / High-Yield Fact**
When managing diabetes in pregnancy, it's essential to use a medication that is safe for both the mother and the fetus. Metformin is a good choice due to its lack of teratogenic potential and its ability to maintain glycemic control without causing fetal hypoglycemia.

**Correct Answer:** C. Metformin